[Skip to content]

European Parkinson's Disease Association
Search our Site
Seventh Framework Programme (FP7)
FP7-­ICT-­2011-­7 [287677 REMPARK]

Start date
November 2011

End date
April 2015

42 months

EPDA representation
Lizzie Graham
Mariella Graziano
Susanna Lindvall
Chiu Man

Full steam ahead
Learn about the REMPARK project


Website:  www.rempark.eu

What is REMPARK?

A significant problem that affects people with Parkinson’s (PwPs) are daily fluctuations in their motor functions. Typically these include tremor, bradykinesia (slow movement), dyskinesia (involuntary and uncontrollable movement), alteration of posture, freezing of gait and falls.

To combat these symptoms is REMPARK, a groundbreaking portable health system that aims to monitor the motor status of PwPs in real time, triggering a series of actions where necessary. REMPARK’s long-term aim is to develop a gait-guidance system that enables PwPs to perform daily activities safely and thereby live life to the full.

How does it work?

REMPARK is a Personal Health System (PHS). The acronym is short for ‘Remote Management of Parkinson’s’. The system includes a smartphone and sensors worn on the body that detect changes in the wearer’s movements and evaluate their on/off dyskinesia status, freezing of gait and falls. The sensors continuously monitor and record data with regards to the wearer’s movements, and sends the data to a central computer server service in the event of a trigger.  The information can be relayed to the PwP’s neurologist or doctor, allowing them to feed into decisions about treatment options. REMPARK will not only enable doctors to improve patient care but will also increase the participation of PwPs in managing their own condition. At the same time, the data will improve knowledge of Parkinson’s, which will lead to more effective management of the disease.

Who is involved?

This European Union-funded REMPARK project – which began in 2011 and is due to be completed in 2015 – brings together the expertise of systems technology experts, researchers and medical experts such as neurologists, psychologists and physiotherapists from across Europe and beyond in an 11-strong consortium.


The EPDA’s role throughout the REMPARK project is one of representing the patient voice. We will ensure that the needs of the PwPs are at the heart of all the decisions made. This, in turn, will have an impact on the usability of the REMPARK system, and will assist in the recruitment process of PwPs from the initial trials leading up to the final REMPARK prototype pilot tests.

One of the EPDA’s main tasks throughout the project is dissemination – in other words, we will ensure that the REMPARK project is well communicated to Parkinson’s organisations across Europe and disseminated to a wider audience through our website, social media, publications and meetings.

There is much more information about the REMPARK project within this section of the website. Use the links on the left to help you navigate. You can also download our REMPARK article here, which provides more information about the project.